In simple terms
The Latin phrase 'in situ' translates to 'in its original place'. Carcinoma in situ means that abnormal cells resembling cancer have grown, but they are trapped within their original surface layer like a seed that has not yet taken root in the deeper soil. Because these cells have not broken through the basement boundary into blood vessels or lymph channels, they cannot spread elsewhere. Finding CIS offers an opportunity to remove or treat the lesion before true invasive cancer develops.
Key takeaways
- Classified clinically as stage 0 cancer.
- Abnormal cells have not penetrated the underlying basement membrane barrier.
- Incapable of distant spread (metastasis) while remaining strictly in situ.
- Treated with local therapies such as surgical excision, ablation, or topical treatments.
Definition
Carcinoma in situ represents the earliest detectable neoplastic phase of epithelial malignancy. Microscopically, the cells exhibit all cytological features of carcinoma—such as cellular pleomorphism, hyperchromasia, and increased mitotic activity—but they remain entirely separated from the underlying connective tissue by an intact basement membrane.
Because the basement membrane serves as a physical barrier containing no blood vessels or lymphatics, CIS lesions are biologically incapable of metastasis while they remain confined. However, left unmanaged, many CIS lesions possess the biological potential to breach the basement membrane and transition into invasive carcinoma.
Why it matters
Receiving a diagnosis of carcinoma in situ is reassuring because the condition is non-invasive and highly curable. At the same time, it requires careful clinical attention. Identifying and treating CIS allows clinicians to eliminate high-risk abnormal cells completely, preventing the development of an invasive malignancy while preserving as much surrounding healthy tissue as possible.
Related biomarkers and tests
Carcinoma in situ is identified through routine screening (such as screening mammography for DCIS or Pap smears for cervical lesions) and confirmed by tissue biopsy. Histopathological assessment with light microscopy confirms that the basement membrane remains completely intact and verifies the absence of stromal invasion.
Related cancers
Common forms of CIS include ductal carcinoma in situ (DCIS) in the breast, squamous intraepithelial lesions or CIS of the cervix, carcinoma in situ of the urinary bladder, and Bowen disease (squamous cell carcinoma in situ) of the skin. CIS can also occur in the larynx and digestive tract.
Related treatments
Because CIS cannot metastasise while contained, treatment focuses entirely on complete local eradication. Standard treatments include surgical excision with clear margins (such as a lumpectomy for DCIS), local ablation, or topical chemotherapy or immunotherapy (such as intravesical BCG for bladder CIS). Systemic chemotherapy is not indicated for carcinoma in situ.
Frequently asked questions
Is carcinoma in situ considered 'real' cancer?
CIS consists of cells that look cancerous under a microscope, but because they have not invaded deeper tissue or spread, some clinicians describe it as pre-invasive disease or stage 0 cancer rather than fully invasive cancer.
Can carcinoma in situ spread to my lymph nodes?
No. As long as the basement membrane remains intact, the abnormal cells cannot reach blood vessels or lymphatic vessels, making spread to lymph nodes or distant organs biologically impossible.
Will I need systemic chemotherapy for carcinoma in situ?
No. Systemic chemotherapy is designed to treat or prevent cancer cells circulating throughout the body. Because CIS is purely local, treatment relies solely on local therapies such as surgery, radiation, or topical treatments.
References
- 1.Ductal Carcinoma In Situ (DCIS)— National Cancer Institute
- 2.Breast Cancer: Stages (Stage 0 / CIS)— American Society of Clinical Oncology
- 3.Non-Muscle-Invasive Bladder Cancer: ESMO Clinical Practice Guidelines— European Society for Medical Oncology
Ask GetOnco AI
Get personalised answers about Carcinoma in Situ (CIS) — Non-Invasive Pre-Cancer from your AI cancer care coordinator.
- Can you explain Carcinoma in Situ (CIS) — Non-Invasive Pre-Cancer in simple words?
- What does Carcinoma in Situ (CIS) — Non-Invasive Pre-Cancer mean for my treatment plan?
- What questions should I ask my oncologist about Carcinoma in Situ (CIS) — Non-Invasive Pre-Cancer?
- What next steps do you recommend regarding Carcinoma in Situ (CIS) — Non-Invasive Pre-Cancer?
GetOnco AI provides educational information and never replaces advice from your medical team.
Explore related topics
More in this section
Glossary terms in this article
Last reviewed August 1, 2026
Medical disclaimer
Educational information only. GetOnco is software, not a medical provider, and does not diagnose disease or recommend treatments. Always discuss your situation with qualified healthcare professionals.